Funding Daily Summary
Funding Daily Summary: What Happened on October 9, 2026
Matchpoint raises $150 million as Forbion raises €2.3 billion
TRex Bio priced a $117 million IPO to fund its immune-drug programs.
-
P
Today in brief
Matchpoint secured $150 million to advance its lead program toward proof of concept, while Forbion raised €2.3 billion in new funds.1 TRex Bio priced an IPO valued at $117 million to support drug development for immunological conditions.2
Matchpoint raises $150 million, Forbion raises €2.3 billion
Matchpoint will use its $150 million Series B to advance its lead program toward proof of concept.1 The company, which is developing drugs for immune and inflammatory diseases, launched four years ago with a $100 million Series A.13
Forbion raised €2.3 billion in new funds, a record capital raise.1
TRex Bio prices $117 million IPO for immune-drug development
TRex Bio priced an IPO valued at $117 million to fund development of drugs for immunological conditions.2 Its programs aim to treat those conditions by activating Treg cells. Eli Lilly is the company's largest equity holder.2